



# STOFARY CITED BY APPLICANT

ATTY. DOCKET:	17341-CIP(AP)	SERIAL NO.: 09/512,110	P.To
APPLICANT:	VOET et al.	TITLE: METHODS FOR TREATING HASHIMOTO'S THYROIDITIS	701783 701783
FILING DATE:	February 24, 2000	GROUP: 1653	10

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CMK	AA	5,667,808	9/16/97	Johnson et al.	424	501	
CHK	AB	5,674,205	10/7/97	Pasricha et al.	604	232	
CMK	AC	5,980,945	11/9/99	Ruiz	424	484	
CMK	AD	6,007,843	12/28/99	Drizen et al.	424	488	
CMK	AE	6,011,011	1/4/00	Hageman	514	12	
CMK	AF	6,022,554	2/8/00	Lee et al.	424	423	
		}				L	

#### FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
Ī	BB						

#### **OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

CMK	CA	Ahren, B.; Cholinergic and VIPergic Effects on Thyroid Hormone Secretion in the Mouse; Peptides; Vol. 6:585-589 (1985).
CMK	СВ	Amenta, F., et al.; Cholinergic Nerves in the Thyroid Gland; Cell and Tissue Res.; 195:367-370 (1978).
CnK	CC	Aoki, K.R.; Preclinical Update on BOTOX® (botulinum Toxin Type A)-Purified Neurotoxin Complex Relative to other Botulinum Neurotoxin Preparations; Eur. J. Neurol; 6(Suppl 4):S3-S10; (1999).
CMK	CD	Boyd, R.S., et al.; The Effect of Botulinum Neurotoxin-B on Insulin Release from a B-Cell Line; Movement Disorders; Vol. 10, No. 3; Item 19; 376 (1995).
CHK	CE	Boyd, R.S., et al.; The Insulin Secreting B-Cell Line HIT-15 Contains SNAP-25 Which is a Target for Botulinum Neurotoxin-A; Movement Disorders; Vol. 10, No. 3; Item 20; 376 (1995).
CITK	CF	Brandi, M.L., et al.; Interaction of VIPergic and Cholinergic Receptors in Human Thyroid Cell; Peptides; Vol. 8:893-897 (1987).

EXAMINER Chi DATE CONSIDERED 10/30/2000

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### . DEPARTMENT OF COMMERCE ATENT AND TRADEMARK OFFICE FORM PTO-1449



Sheet	2	of	3
SHEEL		ΟI	2

ATTY. DOCKET:	17341-CIP(AP)	SERIAL NO.: 09/512,110
APPLICANT:	VOET et al.	TITLE: METHODS FOR TREATING HASHIMOTO'S THYROIDITIS
FILING DATE:	February 24, 2000	GROUP: /653

## **OTHER ART (Continued)**

(Including Author, Title, Date, Pertinent Pages, etc.)

CMK	CG	Braverman, L.E. (Editor); <u>Diseases of the Thyroid</u> ; Humana Press; p. 157 (1997).
CMK	СН	Cardinali, D.P., et al.; Peripheral Neuroendocrinology of the Cervical Autonomic Nervous System; Brazilian J. Med. Biol. Res.; 27:573-599 (1994).
CMK	CI	Fauci, A.S., et al. (Editors); <u>Harrison's Principles of Internal Medicine</u> , 14 <sup>th</sup> Edition; McGraw-Hill (1998). Only two pages supplied
CMK	CJ	Garry, M.G., et al.; "Evaluation of the Efficacy of a Bioerodible Bupivacaine Polymer System on Antinociception and Inflammatory Mediator Release; Pain; 82:49-55 (1999).
CMK	CK	Gonelle-Gispert, C., et al.; SNAP-25A AND -25B Isoforms are Both Expressed in Insulin- Secreting Cells and Can Function in Insulin Secretion; Biochem. J.; 339:159-165 (1999).
CMK	CL	Huffman, L.J., et al.; Muscarinic Modulation of the Vasodilatory Effects of Vasodilatory Effects of Vasoactive Intestinal Peptide at the Rat Thyroid Gland; Neuroendocrinology; 53:69-74 (1991).
CMK	CM	Lakomy, M., et al.; Acetylcholine Esterase Positive Nerves in Swine Thyroid; Z. mikroskanat. Forsch., Leipzig 100:1, S. 34-38 (1986).
CMK	CN	Laskawi, R., et al.; <i>Up-to-Date Report of Botulinum Toxin Type A Treatment in Patients with Gustatory Sweating (Frey's Syndrome)</i> ; <u>Laryngoscope</u> ; 108:381-384 (March 1998).
CMK	CO	Melander, A., et al.; Presence and Influence of Cholinergic Nerves in the Mouse Thyroid; Endocrinology; 105(1):7-9 (1979).
CMK	СР	Powell, E.M., et al.; Controlled Release of Nerve Growth Factor from a Polymeric Implant"; Brain Research; 515:309-311 (1990).
CMK	CQ	Ragona, R.M., et al.; <i>Management of Parotid Sialocele with Botulinum Toxin</i> ; <u>Laryngoscope</u> 109:1344-1346 (August 1999).
CMK	CR	Rao, J.K., et al.; Implantable Controlled Delivery Systems for Proteins Based on Collagen—pHEMA Hydrogels"; Biomaterials; Vol. 15, No. 5; 383-389 (1994).
CMK	CS	Schantz, E.J. et al.; Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine; Microbiological Reviews; Vol. 56, No. 1; 80-99 (March 1992).

**EXAMINER** DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449



Sheet	3	of 3
SHOOL		01

## LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17341-CIP(AP)	SERIAL NO.: 09/512,110
APPLICANT:	VOET et al.	TITLE: METHODS FOR TREATING HASHIMOTO'S THYROIDITIS
FILING DATE:	February 24, 2000	GROUP: 1653

## **OTHER ART (Continued)**

(Including Author, Title, Date, Pertinent Pages, etc.)

Citt	CT	Singh, B.R.; Critical Aspects of Bacterial Protein Toxins; Natural Toxins II; Plenum Press,
CMK		New York; pp. 63-84 (1996).
	CU	Stern, J.E., et al.; Influence of the Autonomic Nervous System on Calcium Homeostasis in the
CMK		Rat; Biol Signals; 3:15-25 (1994).
CMK	CV	Unger, J., et al.; Mechanism of Cholinergic Inhibition of Dog Thyroid Secretion in Vitro;
CMK		Endocrinology; Vol. 114, No. 4; 1266-1271 (1984).
	<u> </u>	Lindoethiology, voi. 111, ive. 1, 1200 1271 (2007)
<u> </u>		
ļ		
:		

EXAMINER DATE CONSIDERED 30/2000

TEXAMINER Listed if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.